WEKO3
AND
アイテム
{"_buckets": {"deposit": "89ae59a8-7925-457e-96bd-b47fac3acdc8"}, "_deposit": {"id": "28007", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "28007"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00028007"}, "item_10_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "214", "bibliographicPageStart": "207", "bibliographicVolumeNumber": "23", "bibliographic_titles": [{"bibliographic_title": "Clinical and Experimental Nephrology"}]}]}, "item_10_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "Background: Recent reports have described the efficacy of rituximab in treating steroid-dependent nephrotic syndrome (SDNS) in pediatric patients. However, few reports describe data regarding adult-onset SDNS. We investigated the efficacy of rituximab for the management of adult-onset SDNS. Methods: We performed a retrospective cohort study investigating eight patients with adult-onset SDNS who were treated with rituximab. Clinical data were obtained at the initiation of rituximab therapy. The primary outcomes evaluated were successful suppression of relapses and CD19+ cells after rituximab treatment. The corticosteroid- and immunosuppressant-sparing effect and adverse events were additionally evaluated. Results: All eight patients were diagnosed with minimal change nephrotic syndrome and received immunosuppressants in addition to corticosteroid. Total number of relapses was 10.5 times as a median value. Rituximab administration was repeated in two patients, whereas six received single-dose rituximab. Three of eight (37.5%) patients showed relapse after rituximab therapy. A rituximab-induced depletion in CD19+ cells noted initially was followed by their reappearance in all patients. There were cases with no relapse after the reappearance of CD19+ cells. The median relapse time pre- and post-rituximab therapy showed a decrease from 1 time/year (interquartile range [IQR] 1\u20133 times/year) to 0 time/year (IQR 0\u20131 time/year). Rituximab treatment induced a significant reduction in the required doses of corticosteroid and cyclosporine (P\u2009\u003c\u20090.01). No serious adverse events were observed. Conclusion: Rituximab treatment was effective not only in childhood-onset but also in adult-onset SDNS. Further studies are needed to establish optimal treatment regimens.", "subitem_description_type": "Abstract"}]}, "item_10_description_5": {"attribute_name": "\u5185\u5bb9\u8a18\u8ff0", "attribute_value_mlt": [{"subitem_description": "\u30d5\u30a1\u30a4\u30eb\u516c\u958b\uff1a2020/02/01", "subitem_description_type": "Other"}]}, "item_10_publisher_32": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "Springer"}]}, "item_10_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1007/s10157-018-1630-y", "subitem_relation_type_select": "DOI"}}]}, "item_10_rights_12": {"attribute_name": "\u6a29\u5229", "attribute_value_mlt": [{"subitem_rights": "\u201cThis is a post-peer-review, pre-copyedit version of an article published in [Clinical and Experimental Nephrology]. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10157-018-1630-y\u201d."}]}, "item_10_select_15": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_61": {"attribute_name": "ISSN\uff08print\uff09", "attribute_value_mlt": [{"subitem_source_identifier": "1342-1751", "subitem_source_identifier_type": "ISSN"}]}, "item_10_source_id_62": {"attribute_name": "ISSN\uff08Online\uff09", "attribute_value_mlt": [{"subitem_source_identifier": "1437-7799", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Katsuno, Takayuki"}], "nameIdentifiers": [{"nameIdentifier": "91208", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masuda, Tomohiro"}], "nameIdentifiers": [{"nameIdentifier": "91209", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saito, Shoji"}], "nameIdentifiers": [{"nameIdentifier": "91210", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kato, Noritoshi"}], "nameIdentifiers": [{"nameIdentifier": "91211", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishimoto, Takuji"}], "nameIdentifiers": [{"nameIdentifier": "91212", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kato, Sawako"}], "nameIdentifiers": [{"nameIdentifier": "91213", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kosugi, Tomoki"}], "nameIdentifiers": [{"nameIdentifier": "91214", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuboi, Naotake"}], "nameIdentifiers": [{"nameIdentifier": "91215", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kitamura, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "91216", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuzuki, Toyonori"}], "nameIdentifiers": [{"nameIdentifier": "91217", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Yasuhiko"}], "nameIdentifiers": [{"nameIdentifier": "91218", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maruyama, Shoichi"}], "nameIdentifiers": [{"nameIdentifier": "91219", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-02-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Therapeutic_Efficacy.pdf", "filesize": [{"value": "269.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 269300.0, "url": {"label": "Therapeutic_Efficacy", "url": "https://nagoya.repo.nii.ac.jp/record/28007/files/Therapeutic_Efficacy.pdf"}, "version_id": "0e45fda6-43a0-446a-a386-c4f05d348668"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "Adult-onset", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Steroid-dependent nephrotic syndrome", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Frequently relapsing nephrotic syndrome", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Minimal change nephrotic syndrome", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Rituximab", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study"}]}, "item_type_id": "10", "owner": "1", "path": ["499/500/501"], "permalink_uri": "http://hdl.handle.net/2237/00030205", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_value": "2019-05-13"}, "publish_date": "2019-05-13", "publish_status": "0", "recid": "28007", "relation": {}, "relation_version_is_last": true, "title": ["Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study"], "weko_shared_id": null}
Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study
http://hdl.handle.net/2237/00030205
e1e00ba3-e239-4c15-956a-e1935850ea77
名前 / ファイル | ライセンス | アクション | |
---|---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-05-13 | |||||
タイトル | ||||||
タイトル | Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study | |||||
著者 |
Katsuno, Takayuki
× Katsuno, Takayuki× Masuda, Tomohiro× Saito, Shoji× Kato, Noritoshi× Ishimoto, Takuji× Kato, Sawako× Kosugi, Tomoki× Tsuboi, Naotake× Kitamura, Hiroshi× Tsuzuki, Toyonori× Ito, Yasuhiko× Maruyama, Shoichi |
|||||
権利 | ||||||
権利情報 | “This is a post-peer-review, pre-copyedit version of an article published in [Clinical and Experimental Nephrology]. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10157-018-1630-y”. | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Adult-onset | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Steroid-dependent nephrotic syndrome | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Frequently relapsing nephrotic syndrome | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Minimal change nephrotic syndrome | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Rituximab | |||||
抄録 | ||||||
内容記述 | Background: Recent reports have described the efficacy of rituximab in treating steroid-dependent nephrotic syndrome (SDNS) in pediatric patients. However, few reports describe data regarding adult-onset SDNS. We investigated the efficacy of rituximab for the management of adult-onset SDNS. Methods: We performed a retrospective cohort study investigating eight patients with adult-onset SDNS who were treated with rituximab. Clinical data were obtained at the initiation of rituximab therapy. The primary outcomes evaluated were successful suppression of relapses and CD19+ cells after rituximab treatment. The corticosteroid- and immunosuppressant-sparing effect and adverse events were additionally evaluated. Results: All eight patients were diagnosed with minimal change nephrotic syndrome and received immunosuppressants in addition to corticosteroid. Total number of relapses was 10.5 times as a median value. Rituximab administration was repeated in two patients, whereas six received single-dose rituximab. Three of eight (37.5%) patients showed relapse after rituximab therapy. A rituximab-induced depletion in CD19+ cells noted initially was followed by their reappearance in all patients. There were cases with no relapse after the reappearance of CD19+ cells. The median relapse time pre- and post-rituximab therapy showed a decrease from 1 time/year (interquartile range [IQR] 1–3 times/year) to 0 time/year (IQR 0–1 time/year). Rituximab treatment induced a significant reduction in the required doses of corticosteroid and cyclosporine (P < 0.01). No serious adverse events were observed. Conclusion: Rituximab treatment was effective not only in childhood-onset but also in adult-onset SDNS. Further studies are needed to establish optimal treatment regimens. | |||||
内容記述タイプ | Abstract | |||||
内容記述 | ||||||
内容記述 | ファイル公開:2020/02/01 | |||||
内容記述タイプ | Other | |||||
出版者 | ||||||
出版者 | Springer | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプresource | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
DOI | ||||||
関連識別子 | ||||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1007/s10157-018-1630-y | |||||
ISSN(print) | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1342-1751 | |||||
ISSN(Online) | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1437-7799 | |||||
書誌情報 |
Clinical and Experimental Nephrology 巻 23, 号 2, p. 207-214, 発行日 2019-02 |
|||||
著者版フラグ | ||||||
値 | author |